Evome Medical Technologies Punctuates Turn Around Plan with Strong Fourth Quarter Resulting in Positive Annual Adjusted EBITDA for Fiscal Year 2023
April 01 2024 - 7:30AM
Evome Medical Technologies Inc. (the “
Company” or
“
Evome”) announced today preliminary annual
financial results for the year ending December 31, 2023. Because of
a strong fourth quarter, the Company generated positive Adjusted
EBITDA for 2023.
Summary of Preliminary Annual Financial Results
for 2023
- Generated annual revenues of $62.6
million
- Generated annual gross margin of
$22.5 million
- Annual gross margin as percentage
of sales of 36%
- Generated annual Adjusted EBITDA of
$852,000
“We can now say with confidence, we have
completed the turn-around of this company,” said CEO Mike Seckler.
“This past year, 2023, was a tale of two different companies. The
first two quarters were frankly calamitous with mounting losses,
unserviceable debt and flat or declining revenues. I was brought
into the company by the Board at the end of June coinciding with
the end of the second quarter. Starting July 1, 2023, the first day
of our third quarter, our team focused on increasing sales, cutting
costs and restructuring our debt to make it manageable and
serviceable. I am very proud of our team at the operating unit
level, they understood the gravity of the situation and we worked
together to make tough decisions that resulted in two consecutive
quarters of positive Adjusted EBITDA. I am pleased with our bankers
who worked with our creditors to restructure our debt to give us
room to turn this company around. I am also grateful that we had
patient creditors that understood and believed in the plan.”
“As our first quarter ends, we continue to make
improvements. But rather than working to shore up the company, we
are working on several fronts to increase revenues and profits. We
are working to reduce debt by divesting non-core business units. We
have also launched our RST product and have several orders. We have
very strong demand internationally and spent the first quarter
retooling our operations to deliver the RST and additional products
overseas. We anticipate this will be reflected in improved revenues
and margins from the second quarter onward. We also plan to launch
the SpaceTek Knee™ product, co-developed by NASA, toward the end of
the year. Because we are driving toward a growing and profitable
business with a normalized level of debt, we are finding more
opportunities to expand our business. I am excited to report our
first quarter accomplishments soon. And lastly, I appreciate our
shareholders support of me and my plan. I believe we have succeeded
in saving this company, now we focus on improving the share
price.”
Unless otherwise specified, all financial
information is presented in Canadian dollars ("$", "dollars" and
"C$") and has been rounded to the nearest hundred thousand. The
Company will file its financial statements for the year ended
December 31, 2023, and related management discussion and analysis
(in the form of an annual report on Form 10-K) on SEDAR+ and with
the United States Securities and Exchange Commission on April 16,
2024.
Mike Seckler Chief Executive Officer Tel: 1
(800) 760-6826 Email: Info@Salonaglobal.com
Cautionary Statements
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Certain statements contained in this press
release constitute "forward-looking information" within the
meaning of the Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities laws. These statements can be
identified by the use of forward-looking terminology such as
“expects” “believes”, “estimates”, "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
and "anticipate", and similar expressions as they relate to the
Company, including: the financial results of 2023; the Company
increasing revenues and profits; the Company reducing debt by
divesting non-core business units; the Company anticipating
improved revenues and margins from the second quarter onward; and
the Company launching its SpaceTek Knee™ product toward the end of
the year. All statements other than statements of historical
fact may be forward-looking information. Such statements reflect
the Company's current views and intentions with respect to future
events, and current information available to the Company, and are
subject to certain risks, uncertainties and assumptions,
including: the completion of normal quarter and year end accounting
procedures and adjustments not resulting in any material
differences; the successful launch and sales of Reactive Step
Trainer (RST) in Q2 which is a higher margin product then the
Company’s existing products; the Company successfully identifying a
buyer for a non-core business and negotiating and closing a sale;
the Company having the necessary capital to complete its business
objectives. The Company cautions that the forward-looking
statements contained herein are qualified by important factors
that could cause actual results to differ materially from those
reflected by such statements. Such factors include but are not
limited to the general business and economic conditions in
the regions in which the Company operates; the ability of the
Company to execute on key priorities, including the successful
completion of acquisitions, business retention, and strategic
plans and to attract, develop and retain key executives;
difficulty integrating newly acquired businesses; ongoing or new
disruptions in the supply chain, the extent and scope of such
supply chain disruptions, and the timing or extent of the
resolution or improvement of such disruptions; the ability to
implement business strategies and pursue business opportunities;
disruptions in or attacks (including cyber-attacks) on the
Company’s information technology, internet, network access or other
voice or data communications systems or services; the evolution
of various types of fraud or other criminal behavior to
which the Company is exposed; the failure of third parties to
comply with their obligations to the Company or its
affiliates; the impact of new and changes to, or application of,
current laws and regulations; granting of permits and licenses in
a highly regulated business; the overall difficult
litigation environment, including in the United States;
increased competition; changes in foreign currency rates;
increased funding costs and market volatility due to market
illiquidity and competition for funding; the availability of
funds and resources to pursue operations; critical accounting
estimates and changes to accounting standards, policies, and
methods used by the Company; the occurrence of natural and
unnatural catastrophic events and claims resulting from
such events; as well as those risk factors discussed or referred
to in the Company’s disclosure documents filed with United
States Securities and Exchange Commission and available at
www.sec.gov, and with the securities regulatory authorities in
certain provinces of Canada and available at www.sedarplus.ca.
Should any factor affect the Company in an unexpected manner, or
should assumptions underlying the forward-looking information
prove incorrect, the actual results or events may differ
materially from the results or events predicted. Any such
forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, the Company
does not assume responsibility for the accuracy or completeness
of such forward-looking information. The forward-looking
information included in this press release is made as of the
date of this press release and the Company undertakes no
obligation to publicly update or revise any forward-looking
information, other than as required by applicable law.
Non-GAAP Measures
This press release refers to "Adjusted EBITDA"
which is a non-GAAP and non-IFRS financial measure that does not
have a standardized meaning prescribed by GAAP or IFRS. The
Company’s presentation of this financial measure may not be
comparable to similarly titled measures used by other companies.
This non-GAAP financial measure assists the Company’s management in
comparing its operating performance over time because certain items
may obscure underlying business trends and make comparisons of
long-term performance difficult, as they are of a nature and/or
size that occur with inconsistent frequency or relate to discrete
acquisition plans that are fundamentally different from the ongoing
operating plans of the Company. The Company’s management also
believes that presenting this measure allows investors to view the
Company’s performance using the same measures that the Company uses
in evaluating its financial and business performance and trends.
“Adjusted EBITDA” is defined as net operating loss excluding
depreciation of property and equipment, amortization of
right-of-use asset, amortization of intangible asset, severance
expense due to restructuring, and stock-based compensation. The
following table provides reconciliation between net operating
(loss) and Adjusted EBITDA:
|
For the year ended December 31, 2023 |
Net operating (loss) |
$ |
(5,544,714 |
) |
Depreciation of property and equipment |
|
1,002,627 |
|
Amortization of right-of-use asset |
|
2,023,956 |
|
Amortization of intangible asset |
|
1,505,108 |
|
Severance Expenses / Restructuring |
|
576,101 |
|
Stock based compensation |
1,288,455 |
|
Adjusted EBITDA |
$ |
851,533 |
|
|
|
|
|
Preliminary Financial
Metrics
This press release contains certain pre-released
financial metrics. The financial metrics contained in this press
release are preliminary and represent the most current information
available to the Company's management, as financial closing
procedures for the fourth quarter and year ended December 31, 2023
are not yet complete. The Company's actual consolidated audited
financial statements for such period may result in material changes
to the financial metrics summarized in this press release
(including by any one financial metric, or all of the financial
metrics, being below or above the figures indicated) as a result of
the completion of normal quarter and year end accounting procedures
and adjustments, and also what one might expect to be in the final
consolidated financial statements based on the financial metrics
summarized in this press release. Although the Company believes the
expectations reflected in this press release are based upon
reasonable assumptions, the Company can give no assurance that
actual results will not differ materially from these
expectations.
Evome Medical Technologies (TSXV:EVMT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Evome Medical Technologies (TSXV:EVMT)
Historical Stock Chart
From Nov 2023 to Nov 2024